Indications and uses
Hartmann's Solution for Injection is indicated as a source of water and electrolytes or as an alkalinizing agent.
Hartmann's Solution for Injection is indicated as a source of water and electrolytes or as an alkalinizing agent.
As directed by a veterinarian. Dosage is dependent upon the age, weight and clinical condition of the patient, as well as laboratory determinations. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit. All solutions for injection contained in plastic containers are intended for administration using sterile equ...
For Animal Use Only
Hartmann's Solution for Injection is a sterile, nonpyrogenic solution for fluid and electrolyte replenishment in single dose containers for parenteral administration. It contains no antimicrobial agents. Discard unused portions.
| Size (mL) | Composition (mg/100mL) | Osmolarity (mOsmol/L) (Calculated) | pH | Ionic Concentration (mEq/L) | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sodium Chloride, USP (NaCl) | Sodium Lactate, USP (C3H5NaO3) | Potassium Chloride, USP (KCl) | Calcium Chloride Dihydrate, USP (CaCl2∙ 2H2O) | Sodium | Potassium | Calcium | Chloride | Lactate | |||
| 3000 | 600 | 317 | 40 | 27 | 278 | 6.5 (5.0 to 7.0) | 131 | 5 | 4 | 111 | 29 |
| 5000 | |||||||||||
Hartmann's Solution for Injection has value as a source of water and electrolytes. lt is capable of inducing diuresis depending on the clinical condition of the patient.
Hartmann's Solution for Injection produces a metabolic alkalinizing effect. Lactate ions are metabolized ultimately to carbon dioxide and water, which requires the consumption of hydrogen cations.
Hartmann's Solution for Injection is indicated as a source of water and electrolytes or as an alkalinizing agent.
Do not administer to horses by intraperitoneal injection.
Hartmann's Solution for Injection should be used with great care, if at all, in patients with congestive heart failure, severe renal insufficiency, and in clinical states in which there exists edema with sodium retention.
Hartmann's Solution for Injection should be used with great care, if at all, in patients with hyperkalemia, severe renal failure, and in conditions in which potassium retention is present.
Hartmann's Solution for Injection should be used with great care in patients with metabolic or respiratory alkalosis. The administration of lactate ions should be done with great care in those conditions in which there is an increased level or an impaired utilization of these ions, such as severe hepatic insufficiency.
Hartmann's Solution for Injection should not be administered simultaneously with blood through the same administration set because of the likelihood of coagulation.
The parenteral administration of Hartmann's Solution for Injection can cause fluid and/or solute overloading resulting in dilution of serum electrolyte concentrations, overhydration, congested states, or pulmonary edema. The risk of dilutional states is inversely proportional to the electrolyte concentrations of the injections. The risk of solute overload causing congested states with peripheral and pulmonary edema is directly proportional to the electrolyte concentrations of the injection.
In patients with diminished renal function, administration of Hartmann's Solution for Injection may result in sodium or potassium retention.
Hartmann's Solution for Injection is not for use in the treatment of lactic acidosis.
Reactions which may occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation, and hypervolemia. If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures, and save the remainder of the fluid for examination if deemed necessary.
Clinical evaluation and periodic laboratory determinations are necessary to monitor changes in fluid balance, electrolyte concentrations, and acid base balance during prolonged parenteral therapy or whenever the condition of the patient warrants such evaluation.
Hartmann's Solution for Injection must be used with caution. Excess administration may result in metabolic alkalosis.
Do not administer unless solution is clear and seal is intact.
Reactions which may occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation, and hypervolemia.
lf an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures, and save the remainder of the fluid for examination if deemed necessary.
As directed by a veterinarian. Dosage is dependent upon the age, weight and clinical condition of the patient, as well as laboratory determinations.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.
All solutions for injection contained in plastic containers are intended for administration using sterile equipment and aseptic technique.
Additives may be incompatible. Complete information is not available. Those additives known to be incompatible should not be used. Consult with pharmacist, if available. If, in the informed judgment of the veterinarian, it is deemed advisable to introduce additives, use aseptic technique. Mix thoroughly when additives have been introduced. Do not store solutions containing additives. Discard unused portion.
In an event of overhydration or solute overload, re-evaluate the patient and institute appropriate corrective measures.
See Warnings, Adverse Reactions and Precautions.
Hartmann's Solution for Injection is supplied in plastic bags as follows:
* Latex Free Bag. The plastic container is fabricated from a specially formulated polyvinyl chloride. The amount of water that can permeate from inside the container into the overwrap is insufficient to affect the solution significantly. Solutions in contact with the plastic container can leach out certain of its chemical components in very small amounts within the expiration period, e.g., di-2-ethylhexyl phthalate (DEHP), up to 5 parts per million. However, the safety of the plastic has been confirmed in animals according to USP biological tests for plastic containers, as well as tissue culture toxicity studies.
STORAGE: Exposure of pharmaceutical products to heat should be minimized. Avoid excessive heat. It is recommended the product be stored in the moisture barrier overwrap at room temperature (25°C/77°F); brief exposure up to 40°C/104°F does not adversely affect the product.
Tear overwrap down side at slit and remove solution bag. Some opacity of the plastic due to moisture absorption during the sterilization process may be observed. This is normal and does not affect the solution quality or safety. The opacity will diminish gradually. Check for minute leaks by squeezing inner bag firmly. If leaks are found, discard solution as sterility may be impaired.
If supplemental medication is desired, follow directions below.
WARNING: Additives may be incompatible.
To add medication before solution administration
To add medication during solution administration
CAUTION: Federal law (U.S.A.) restricts this drug to use by or on the order of a licensed veterinarian.
DISTRIBUTED BY:
Dechra Veterinary Products
7015 College Boulevard, Suite 525 Overland Park, KS 66211
Made in El Salvador.
For a copy of the Safety Data Sheet (SDS) or to report adverse reactions call
Dechra Veterinary Products at (866) 933-2472.
© 2017 Dechra Ltd.
VETIVEX® is a trademark of Dechra Ltd; all rights reserved.
Rev. 10/17
Vetivex®
Hartmann's Solution for Injection
STERILE - NONPYROGENIC SOLUTION
FOR ANIMAL USE ONLY
KEEP OUT OF REACH OF CHILDREN
CAUTION: FEDERAL LAW (U.S.A.) RESTRICTS THIS DRUG TO USE BY
OR ON THE ORDER OF A LICENSED VETERINARIAN.
NDC: 17033-482-03
3000 mL
Dechra

| Class | Version | Type | Effective |
|---|---|---|---|
| SODIUM CATION Pharmacologic Class Indexing | 2 | Indexing - Pharmacologic Class | 20180813 |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 17033-482-03 | Vetivex Hartmanns | 3000 mL in 1 CONTAINER | INJECTION, SOLUTION | 3000 | 3 | |
| 17033-482-05 | Vetivex Hartmanns | 5000 mL in 1 CONTAINER | INJECTION, SOLUTION | 5000 | 3 |
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 17033-482 | VETIVEX HARTMANNS (SODIUM CHLORIDE, SODIUM LACTATE, POTASSIUM CHLORIDE, AND CALCIUM CHLORIDE) INJECTION, SOLUTION [DECHRA VETERINARY PRODUCTS] | 3 | 2 package rows | 20201022_c4cfde4d-672b-4d5f-aced-e2b7fc1ef593.zip |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 17033-482 | 17033-482-03, 17033-482-05 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| Sodium chloride | 451W47IQ8X | ACTIB |
| Sodium Lactate | TU7HW0W0QT | ACTIB |
| Potassium Chloride | 660YQ98I10 | ACTIB |
| Calcium Chloride | M4I0D6VV5M | ACTIB |
| Water | 059QF0KO0R | IACT |
| Sodium | 9NEZ333N27 | IACT |
| Potassium | RWP5GA015D | IACT |
| Calcium | SY7Q814VUP | IACT |
| Chloride ion | Q32ZN48698 | IACT |
| Lactic acid, unspecified form | 33X04XA5AT | IACT |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Nacl 0.9% Normal Saline Solution | SODIUM CHLORIDE | CHI FUNG TECHNOLOGY COMPANY | 5a53c4c8-c9de-700c-e063-6394a90a3ab5 | 2026-08-31 | Warnings | SODIUM CHLORIDE |
| Sodium Chloride | SODIUM CHLORIDE | YYBA CORP | 597f3347-647c-3545-e063-6294a90abab2 | 2026-08-20 | Warnings | SODIUM CHLORIDE |
| Sodium Chloride | SODIUM CHLORIDE | Fresenius Kabi USA, LLC | 2e5fe9f4-78e5-4af4-8bf9-9680e5dc5e88 | 2026-08-20 | Warnings, Adverse reactions | SODIUM CHLORIDE |
| Hypertonic Saline | SODIUM CHLORIDE | NAVEH PHARMA (1996) LTD | 167c7a9c-1228-4fb2-a89c-d3e148386323 | 2026-07-30 | Warnings | SODIUM CHLORIDE |
| Hypertonic Saline Solution Sodium Chloride | SODIUM CHLORIDE | NAVEH PHARMA (1996) LTD | 750ea4b1-de2b-4299-aaa2-331daf383d0d | 2026-07-30 | Warnings | SODIUM CHLORIDE |
| Sodium Chloride | SODIUM CHLORIDE | Fresenius Medical Care de Mexico, S.A. de C.V. | 9a1220fb-6853-45ae-838c-10d8596e1af7 | 2026-07-27 | Warnings, Adverse reactions | SODIUM CHLORIDE |
| Sodium Chloride | SODIUM CHLORIDE | Fresenius Medical Care Renal Therapies Group, LLC | af5cdf1a-19f4-11e2-892e-0800200c9a66 | 2026-07-27 | Warnings, Adverse reactions | SODIUM CHLORIDE |
| Sodium Chloride | SODIUM CHLORIDE | LABORATORIOS GRIFOLS SA | eb811d79-fdb8-1f1a-c2ad-1cc4bfc7eadf | 2026-07-15 | Warnings, Adverse reactions | SODIUM CHLORIDE |
| WHWSWB 0.9% Saline | SODIUM CHLORIDE | Yiwu Huanshu E-commerce Co., Ltd | 4e9c21e5-f2f9-90e4-e063-6394a90acfe2 | 2026-07-11 | Warnings | SODIUM CHLORIDE |
| WHWSWB 0.9% SALINE | SODIUM CHLORIDE | Yiwu Huanshu E-commerce Co., Ltd | 5082b773-79b2-2501-e063-6394a90a170f | 2026-07-11 | Warnings | SODIUM CHLORIDE |
| SALINE NASAL | SODIUM CHLORIDE | ALAINA HEALTHCARE PRIVATE LIMITED | ed30a7f9-7132-42da-9bed-63a9b1c80ab2 | 2026-07-07 | Warnings | SODIUM CHLORIDE |
| OHTrust Artifical Eyedrop | SODIUM CHLORIDE | Nanoplus Technology Co., Limited | 2ea26d96-704b-17bb-e063-6394a90a7e27 | 2026-07-01 | Warnings | SODIUM CHLORIDE |
| 0.9% Sodium Chloride Saline Solution | SODIUM CHLORIDE | Yunqi Cosmetics (Shenzhen) Co., Ltd | 546af257-dbd1-11fc-e063-6394a90a8e0a | 2026-06-16 | Warnings | SODIUM CHLORIDE |
| Sodium Chloride | SODIUM CHLORIDE | Cardinal Health 107, LLC | 107af8bc-b6af-4b85-8c8a-ea757dcef1da | 2026-06-12 | Adverse reactions | SODIUM CHLORIDE |
| SALINE CLEANING | SODIUM CHLORIDE | Guangzhou Huanmei Cosmetics Co., Ltd. | 524f07cc-ddb9-dda5-e063-6394a90ac0a5 | 2026-05-21 | Warnings | SODIUM CHLORIDE |
| Sodium Chloride | SODIUM CHLORIDE | Hospira, Inc. | a2a964f7-c3ec-4dfb-e3a0-6d8136a80397 | 2026-05-19 | Warnings, Adverse reactions | SODIUM CHLORIDE |
| Sodium Chloride | SODIUM CHLORIDE | Sportpharm LLC | a2c111f6-74d5-4a5d-82ac-d0f237488cb8 | 2026-04-24 | Warnings, Adverse reactions | SODIUM CHLORIDE |
| Sodium Chloride | SODIUM CHLORIDE | Method Pharmaceuticals, LLC | 4b08859e-65bd-8255-e063-6394a90af614 | 2026-04-23 | Warnings | SODIUM CHLORIDE |
| SODIUM CHLORIDE 1 GRAM | SODIUM CHLORIDE | Gendose Pharmaceuticals, LLC | ce988ae5-61c6-4324-90e1-a94c8a54d0d0 | 2026-04-13 | Warnings | SODIUM CHLORIDE |
| Walgreens Sodium Chloride Ophthalmic 5 Percent Hypertonicity Eye | SODIUM CHLORIDE | Walgreen Company | bda3b9db-5fc4-408c-a5ae-d1eeb3ee308d | 2026-04-06 | Warnings | SODIUM CHLORIDE |
Adverse event summaries are temporarily unavailable. Other product information remains available.